Breathing New Life into Mental Health Treatment: An Interview with Freespira, Inc.

Interview with Freespira, Inc.

AlphaFund: Welcome to AlphaFund’s interview series, where we spotlight innovative companies making waves in their industries. Today, we’re thrilled to have with us Freespira, Inc., a company revolutionizing the treatment of panic disorder and post-traumatic stress disorder (PTSD). Can you tell us about your company’s journey and the problem you’re solving?

Freespira, Inc.: Thank you for having us. At Freespira, we’re dedicated to providing accessible, drug-free, and effective treatment for individuals struggling with panic disorder and PTSD. These conditions can be incredibly debilitating, affecting millions of people worldwide. Traditional treatments, such as medication and therapy, while helpful, don’t work for everyone. We saw a need for a new approach, one that empowers patients to take control of their symptoms and improve their quality of life.

AlphaFund: That’s a powerful mission. How does your solution work, and what sets it apart from other treatments?

Freespira, Inc.: Our solution is a unique, evidence-based digital therapeutic device that guides patients through a personalized breathing training program. The device is a small, handheld sensor that measures the patient’s breathing rate and pattern in real-time. It connects to an app that provides visual and auditory feedback, helping the patient adjust their breathing to a therapeutic rate and pattern.

What sets our approach apart is that it’s drug-free, non-invasive, and can be done in the comfort of the patient’s own home. It’s also highly effective, with clinical studies showing that 85% of patients experience significant symptom reduction after just four weeks of treatment.

AlphaFund: Those results are impressive. Can you share more about the science behind your device and how it was developed?

Freespira, Inc.: Our device is based on years of research into the role of respiratory dysregulation in panic disorder and PTSD. Many people with these conditions exhibit chronic hyperventilation and irregular breathing patterns, which can exacerbate symptoms. By training patients to normalize their breathing, we can help them reduce the frequency and intensity of their symptoms.

Our team of experts, including psychologists, physicians, and engineers, worked together to develop a device that’s easy to use, reliable, and effective. We’ve conducted multiple clinical trials to validate our approach and continue to gather data to refine and improve our treatment.

AlphaFund: As a company, what stage are you at now, and what are your plans for growth?

Freespira, Inc.: We’ve been in the market for several years now and have seen strong adoption from both healthcare providers and patients. We’re currently focused on expanding our reach and making our device more widely available. We’re also exploring partnerships with insurance companies to increase access and affordability.

Looking ahead, we see significant potential for our technology beyond panic disorder and PTSD. We’re investigating applications for other anxiety disorders, as well as chronic pain conditions, where breathing dysregulation also plays a role. Our ultimate goal is to become the leading provider of drug-free, digital therapeutics for a wide range of mental health and chronic pain conditions.

AlphaFund: As a startup in the healthcare space, what challenges have you faced in bringing your product to market, and how have you overcome them?

Freespira, Inc.: One of the main challenges we’ve faced is navigating the complex regulatory landscape for digital therapeutics. We’ve had to work closely with the FDA to ensure that our device meets all necessary safety and efficacy standards. It’s been a lengthy and rigorous process, but we believe it’s essential to ensure that patients receive the highest quality care.

Another challenge has been educating healthcare providers and patients about the benefits of our approach. Many people are still unfamiliar with digital therapeutics and may be hesitant to try something new. We’ve invested heavily in outreach and education to build trust and demonstrate the value of our treatment.

AlphaFund: Thank you for sharing those insights. As you look to raise your next round of funding, what are your key priorities, and what kind of investors are you looking to partner with?

Freespira, Inc.: Our key priorities for the next round of funding are to accelerate our commercialization efforts, expand our clinical evidence base, and invest in R&D to develop new applications for our technology. We’re looking for investors who share our vision for transforming mental health and chronic pain treatment with digital therapeutics.

Ideally, we’d like to partner with investors who have experience in the healthcare and technology sectors and can provide strategic guidance as we scale. We’re also interested in investors who are passionate about our mission and are committed to making a positive impact on patients’ lives.

AlphaFund: Before we wrap up, can you share a bit about your company culture and the team behind Freespira?

Freespira, Inc.: Absolutely. Our team is the heart and soul of Freespira. We have a passionate, dedicated group of individuals who are committed to making a difference in the lives of people with panic disorder and PTSD. Our culture is built on collaboration, innovation, and a shared sense of purpose.

We believe in fostering an environment where everyone’s voice is heard, and ideas are celebrated. We encourage our team members to take ownership of their work and to continuously learn and grow. We also place a strong emphasis on work-life balance and mental health, as we believe that taking care of our team is essential to our success.

AlphaFund: That’s wonderful to hear. How has your company culture evolved as you’ve grown, and what steps are you taking to maintain it as you scale?

Freespira, Inc.: As we’ve grown, we’ve had to be intentional about preserving our culture and values. We’ve implemented regular team-building activities, employee recognition programs, and open forums for feedback and discussion. We also have a dedicated People Operations team that focuses on recruitment, onboarding, and employee engagement to ensure that our culture remains strong as we bring on new team members.

Looking ahead, we plan to continue investing in our people and culture. We believe that building a great company starts with building a great team, and we’re committed to creating an environment where everyone can thrive.

AlphaFund: Thank you for sharing those insights. One final question – what advice would you give to other founders who are looking to build a mission-driven company in the healthcare space?

Freespira, Inc.: My advice would be to stay focused on your mission and the impact you want to make. Building a healthcare company can be challenging, with long development timelines, regulatory hurdles, and complex reimbursement models. It’s easy to get discouraged or sidetracked along the way.

But if you stay true to your vision and keep the needs of patients at the forefront, you’ll be able to navigate those challenges and build something truly meaningful. Surround yourself with a great team, seek out mentors and advisors, and don’t be afraid to ask for help when you need it.

AlphaFund: That’s great advice. Thank you again for taking the time to speak with us today. We’re excited to see what the future holds for Freespira and wish you all the best in your journey ahead.


Q: What conditions does Freespira’s device treat?

A: Freespira’s device is currently used to treat panic disorder and post-traumatic stress disorder (PTSD). The company is also exploring applications for other anxiety disorders and chronic pain conditions.

Q: How long does the treatment with Freespira’s device take?

A: Clinical studies have shown that 85% of patients experience significant symptom reduction after just four weeks of treatment with Freespira’s device.

Q: Is Freespira’s treatment FDA-approved?

A: Freespira has worked closely with the FDA to ensure that their device meets all necessary safety and efficacy standards. The device is cleared by the FDA for the treatment of panic disorder and PTSD.

Q: How much does treatment with Freespira’s device cost?

A: The cost of treatment varies depending on insurance coverage. Freespira is working with insurance companies to increase access and affordability for patients.

Q: Can Freespira’s device be used in conjunction with other treatments, such as medication or therapy?

A: Yes, Freespira’s device is designed to complement other treatments and can be used in conjunction with medication and therapy as recommended by a healthcare provider.

Q: How does Freespira’s device differ from traditional breathing exercises?

A: Freespira’s device provides real-time, personalized feedback to guide patients through a therapeutic breathing pattern. This targeted approach has been clinically proven to be more effective than traditional breathing exercises alone.

Q: Is Freespira’s device suitable for children?

A: Currently, Freespira’s device is intended for use by adults aged 18 and older. The company is investigating potential applications for adolescents and children with anxiety disorders.

Q: Does Freespira offer customer support for patients using their device?

A: Yes, Freespira offers comprehensive customer support for patients, including onboarding assistance, technical troubleshooting, and ongoing support throughout the treatment process. Patients can access support via phone, email, or the Freespira app.

About AlphaFund:

AlphaFund is a leading magazine that showcases innovative startups and their founders who are seeking to raise their next round of funding. Our mission is to provide a platform for these companies to share their stories, visions, and challenges with a wide audience of investors, entrepreneurs, and business enthusiasts.

We feature companies from various industries, including healthcare, technology, sustainability, finance, and more. Our team of experienced journalists conducts in-depth interviews with founders to gain insights into their company’s journey, the problems they’re solving, and their plans for growth.

At AlphaFund, we believe in the power of storytelling to connect startups with potential investors and partners. We strive to create engaging, informative content that highlights the most promising and innovative companies in their respective fields.

Our magazine reaches a diverse audience of venture capitalists, angel investors, family offices, and corporate innovation teams. By sharing these startup stories, we aim to facilitate meaningful connections and help founders secure the funding and resources they need to bring their vision to life.

Our goal is to be a trusted partner for startups at every stage of their journey, from idea to IPO. Whether you’re a first-time founder just starting out or a seasoned entrepreneur looking to scale, we’re here to help you navigate the challenges and opportunities of building a successful company.

Stay in the Loop

Join our mailing list to stay in the loop to stay informed, for free.

Latest stories

You might also like...